BeOne Medicines Partners with Revolution Medicines on RAS Cancer Therapies
San Carlos, Calif. & Redwood City, Calif., August 10, 2026 BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a...
zoldonrasib
Advertisement
Revolution Medicines Reports Promising Phase 1/2 Zoldonrasib Combination Data in Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., July 2, 2026 Revolution Medicines announced encouraging Phase 1/2 clinical results for its investigational RAS(ON) G12D-selective...
Revolution Medicines Presents RAS(ON) Data at ESMO 2026
REDWOOD CITY, Calif., June 24, 2026 Revolution Medicines announced that new clinical data from its innovative RAS(ON) inhibitor portfolio...
Revolution Medicines Reports Breakthrough Zoldonrasib Data
REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...
Advertisement
